Jana Hundertmark
Charité - Universitätsmedizin Berlin · 26 works · 1,337 citations · h-index 12
Top works
- Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages☆
- Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis
- Single Cell RNA Sequencing Identifies Subsets of Hepatic Stellate Cells and Myofibroblasts in Liver Fibrosis
- Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis
- Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling
- The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis
- Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases
- Adapted Immune Responses of Myeloid-Derived Cells in Fatty Liver Disease
- Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis
- Expression of Cyclin E1 in hepatic stellate cells is critical for the induction and progression of liver fibrosis and hepatocellular carcinoma in mice
- Dissecting Acute Drug‐Induced Hepatotoxicity and Therapeutic Responses of Steatotic Liver Disease Using Primary Mouse Liver and Blood Cells in a Liver‐On‐A‐Chip Model
- Single Cell RNA Sequencing in NASH
- How effective are nonalcoholic fatty liver disease models for drug discovery?
- Dissecting NAFLD pathomechanisms using primary mouse liver and blood cells in a microfluidic perfusable compartmentalized liver-on-a-chip model
- PS-007-Differential therapeutic effects of pan- and single PPAR agonists on steatosis, inflammation, macrophage composition and fibrosis in a murine model of non-alcoholic steatohepatitis
- THU-037 Lycorine reduces liver fibrosis by inactivating hepatic stellate cells (HSCs) in mouse models of metabolic dysfunction-associated steatohepatitis (MASH)
- Combination therapy with a dual CCR2/CCR5 antagonist and a FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis
- PS-004-Western diet triggers a unique inflammatory phenotype of myeloid leukocytes in bone marrow and liver
- Inhibition of the chemokine CXCL12 promotes liver cancer progression by modulating the inflammatory and angiogenic tumor microenvironment
- FRI-457 CXCL12 restricts hepatocellular carcinoma progression by shaping the tumor microenvironment in liver fibrosis